Covid: EU reserves 15 million doses of modified Moderna vaccine


They are part of the overall order for 460 million doses placed with Moderna, on behalf of the Twenty-Seven, by the Commission since the start of the pandemic.

The European Commission has reserved with the American biotech Moderna 15 million additional doses of the new version of its anti-Covid vaccine, modified in particular according to the Omicron variant.

The European Medicines Agency (EMA), regulator of the sector, announced in mid-June that it had begun to examine this new version, intended to target both the original strain of SARS CoV-2 and that of the Omicron variant, including sub- variants have recently led to an increase in infections.

SEE ALSO – Covid-19: Pedro Sanchez welcomes the signing by the EU of a contract for a new Spanish vaccine

Changes in delivery schedules

However, the agreement reached by the Commission remains subject to the green light from European regulators, “subject to marketing authorization (in the EU) within a time frame that would allow the use of these doses for vaccination campaignsthis fall and winter, according to a press release. These 15 million are part of the overall order for 460 million doses placed with Moderna, on behalf of the Twenty-Seven, by the Commission since the start of the pandemic. The lab uses messenger RNA technology.

At the beginning of June, the European executive announced that it had reached an agreement with the New York biotech so that “a part» doses whose delivery was expected in the second quarter can only be delivered from September, in the form of booster vaccines adapted to SARS CoV-2 variants, including Omicron. Brussels announced on Tuesday that it had reached an agreement with Moderna to once again adjust the schedule, this time by postponing to September and during the autumn and then the winter the supply of doses whose delivery was initially scheduled for this summer.

SEE ALSO – Covid: “The government has no intention of relaxing the pressure on the population”

It’s about “to better respond to the needs of Member States“this fall and winter, “when they are more likely to need additional stocks for their national (vaccination) campaigns and fulfilling their international solidarity commitments“, explained the Commission. “The agreement also ensures that, if one or more adapted vaccines (to the variants) receive marketing authorisation, Member States can choose to receive these adapted vaccines under the current contract.», Specifies the European executive.



Source link -93